ASPREVA PHARMACEUTICALS APPOINTS WILLIAM L. HUNTER, CEO OF ANGIOTECH PHARMACEUTICALS, TO ITS BOARD OF DIRECTORS

Aspreva Pharmaceuticals Corporation, an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today announced that William Hunter, MD, MSc has been appointed to the Company's Board of Directors.

CNW Group (http://www.newswire.ca/en/releases/archive/June2006/13/c4284.html)